DK1117403T3 - MGLUR5-antagonister til behandling af smerte og angst - Google Patents

MGLUR5-antagonister til behandling af smerte og angst

Info

Publication number
DK1117403T3
DK1117403T3 DK99948905T DK99948905T DK1117403T3 DK 1117403 T3 DK1117403 T3 DK 1117403T3 DK 99948905 T DK99948905 T DK 99948905T DK 99948905 T DK99948905 T DK 99948905T DK 1117403 T3 DK1117403 T3 DK 1117403T3
Authority
DK
Denmark
Prior art keywords
pain
treatment
anxiety
antagonists
mglur5 antagonists
Prior art date
Application number
DK99948905T
Other languages
Danish (da)
English (en)
Inventor
Hans Allgeier
Nicholas David Cosford
Fabrizio Gasparini
Conrad Gentsch
Stephen D Hess
Edwin Carl Johnson
Rainer Kuhn
Laszlo Urban
Mark Andrew Varney
Elebi Goenuel Veli
Katharine Walker
Peter Josef Flor
Mark Tricklebank
Original Assignee
Sibia Neurosciences Inc
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26314451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1117403(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9821503.1A external-priority patent/GB9821503D0/en
Application filed by Sibia Neurosciences Inc, Novartis Ag filed Critical Sibia Neurosciences Inc
Application granted granted Critical
Publication of DK1117403T3 publication Critical patent/DK1117403T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DK99948905T 1998-10-02 1999-09-30 MGLUR5-antagonister til behandling af smerte og angst DK1117403T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9821503.1A GB9821503D0 (en) 1998-10-02 1998-10-02 Organic compounds
US22081398A 1998-12-23 1998-12-23
PCT/EP1999/007239 WO2000020001A1 (en) 1998-10-02 1999-09-30 Mglur5 antagonists for the treatment of pain and anxiety

Publications (1)

Publication Number Publication Date
DK1117403T3 true DK1117403T3 (da) 2004-04-13

Family

ID=26314451

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99948905T DK1117403T3 (da) 1998-10-02 1999-09-30 MGLUR5-antagonister til behandling af smerte og angst

Country Status (21)

Country Link
EP (1) EP1117403B1 (pt)
JP (1) JP2002526408A (pt)
KR (1) KR20010088832A (pt)
CN (1) CN1187048C (pt)
AT (1) ATE255894T1 (pt)
AU (1) AU765644B2 (pt)
BR (1) BR9914215A (pt)
CA (1) CA2345137A1 (pt)
DE (1) DE69913548T2 (pt)
DK (1) DK1117403T3 (pt)
ES (1) ES2213389T3 (pt)
HU (1) HUP0200553A3 (pt)
ID (1) ID29095A (pt)
IL (2) IL142047A0 (pt)
NO (1) NO20011440L (pt)
NZ (1) NZ510743A (pt)
PL (1) PL202906B1 (pt)
PT (1) PT1117403E (pt)
RU (1) RU2232017C2 (pt)
SK (1) SK4382001A3 (pt)
WO (1) WO2000020001A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0005700D0 (en) * 2000-03-09 2000-05-03 Glaxo Group Ltd Therapy
CA2432077C (en) 2000-12-22 2011-01-18 F. Hoffmann-La Roche Ag Tetrahydro-(benzo or thieno)-azepine-pyrazine and triazine derivatives as mglur 1 antagonists
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
SE0303419D0 (sv) * 2003-12-17 2003-12-17 Astrazeneca Ab New use 11
SE0303418D0 (sv) * 2003-12-17 2003-12-17 Astrazeneca Ab New use 1
FR2883180B1 (fr) * 2005-03-18 2007-05-25 Pierre Fabre Medicament Sa Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
DE102005062985A1 (de) * 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte bis(hetero)aromatische N-Ethylpropiolamide und ihre Verwendung zur Herstellung von Arzneimitteln
CA2670116C (en) 2006-11-22 2015-03-10 Seaside Therapeutics, Llc Methods of treating mental retardation, down's syndrome, fragile x syndrome and autism
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
US8586581B2 (en) * 2009-12-17 2013-11-19 Hoffmann-La Roche Inc Ethynyl compounds useful for treatment of CNS disorders
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
AR080055A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
WO2011109398A2 (en) 2010-03-02 2011-09-09 President And Fellows Of Harvard College Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
US20110294879A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders
US20120016021A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
WO2012054724A1 (en) 2010-10-21 2012-04-26 Massachusetts Institute Of Technology Methods of treating seizure disorders
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
EP2557183A1 (de) 2011-08-12 2013-02-13 Siemens Aktiengesellschaft Verfahren zum Betrieb einer Konti-Glühe für die Verarbeitung eines Walzguts
AU2013255458A1 (en) 2012-05-03 2014-10-09 Novartis Ag L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists
CN107849006B (zh) 2015-06-03 2020-11-13 豪夫迈·罗氏有限公司 乙炔基衍生物
WO2019025931A1 (en) 2017-07-31 2019-02-07 Novartis Ag USE OF A MUSSEL FOR REDUCING THE USE OF COCAINE OR FOR PREVENTING A RECHUTE IN THE USE OF COCAINE
EP3459939A1 (en) 2017-09-26 2019-03-27 Pragma Therapeutics Novel heterocyclic compounds as modulators of mglur7

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives

Also Published As

Publication number Publication date
CA2345137A1 (en) 2000-04-13
AU765644B2 (en) 2003-09-25
HUP0200553A2 (hu) 2002-07-29
NO20011440D0 (no) 2001-03-21
ID29095A (id) 2001-07-26
RU2232017C2 (ru) 2004-07-10
NO20011440L (no) 2001-05-15
CN1187048C (zh) 2005-02-02
BR9914215A (pt) 2001-07-03
CN1321087A (zh) 2001-11-07
KR20010088832A (ko) 2001-09-28
DE69913548D1 (de) 2004-01-22
PL346876A1 (en) 2002-03-11
HUP0200553A3 (en) 2002-11-28
DE69913548T2 (de) 2004-09-23
JP2002526408A (ja) 2002-08-20
EP1117403B1 (en) 2003-12-10
PT1117403E (pt) 2004-04-30
WO2000020001A1 (en) 2000-04-13
SK4382001A3 (en) 2001-08-06
PL202906B1 (pl) 2009-08-31
IL142047A0 (en) 2002-03-10
EP1117403A1 (en) 2001-07-25
NZ510743A (en) 2003-10-31
ATE255894T1 (de) 2003-12-15
IL142047A (en) 2007-09-20
ES2213389T3 (es) 2004-08-16
AU6198499A (en) 2000-04-26

Similar Documents

Publication Publication Date Title
DK1117403T3 (da) MGLUR5-antagonister til behandling af smerte og angst
DK1196172T3 (da) (S,S)-reboxetin til behandling af kronisk smerte
NO20004935D0 (no) Anordning til den transdermale avleveringen av diklofenak
IS2494B (is) Notkun á morfólínóli til meðhöndlunar á kynferðislegri vanvirkni
ATE314371T1 (de) Spiro-indole als y5-rezeptor antagonisten
DE60118544D1 (de) Methoden und zusammensetzungen zur modulation der aktivität der alpha-adrenergen rezeptoren
IS6560A (is) Lyfjasamsetning fyrir meðhöndlun á bráðum, þrálátum sársauka og/eða taugakerfissársauka og mígreni
DK1063990T3 (da) Anvendelse af Biochanin-beriget ekstrakt til behandling af östrogen-associerede lidelser
CY1107531T1 (el) Χρηση αναστολεων πρωτεασομης για την αγωγη των διαταραχων ξηρου οφθαλμου
NO20030213D0 (no) Anvendelse av D2/D3 reseptor-agonister for behandling av fibromyalgi
DE60108857D1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
DK1282616T3 (da) Hydroxyphenylpiperidin-4-ylidenmethylbenzamidderivater til behandling af smerter
ATE266420T1 (de) Kombinationspräparat, das selektive nmda nr2b- antagonisten und cox-2 inhibitoren enthält
DK1200081T3 (da) Anvendelse af escitalopram til behandling af generaliseret angstlidelse
DE50114605D1 (de) No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
NO20024776D0 (no) Hydroksyfenyl-piperazinyl-metyl-benzamidderivater til behandling av smerte
NO20024777D0 (no) Kinolinyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
ATE358483T1 (de) Selektive dopamin-d4-rezeptoragonisten zur behandlung von sexuellen dysfunktionen
BR0314139A (pt) Derivados de 1,4-pirazina substituìdos
DE69930844D1 (de) Inhibitoren von mycobakterien
DK1150682T3 (da) Ubichinon Qn til behandling af migrænesmerter
BR0206918A (pt) Uso de iloperidona
NO20062138L (no) Anvendelse av ifenprodil i behandling av smerte
DK1286986T3 (da) Quinolinylpiperidin-4-ylidenmethylbenzamidderivater til behandling af smerte